Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC

Trial Details

NCT ID

NCT06643793

Phase

PHASE2

Sponsor

Affiliated Hospital of Nantong University

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Irinotecan liposome (ll) + 5-FU/LV + bevacizumab

Locations (sample)

• Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

• Age ≥ 18 years old and ≤ 75 years old, gender is not limited;
• Diagnosis of colorectal cancer by histopathology and/or cytology, clinical Records showing inoperable advanced metastatic colon or rectal cancer (i…
• At least 1 measurable target lesion according to RECIST v1.1 criteria (ie, non-nodal lesions with a CT scan length ≥10 mm and nodal lesions with a …
• Prior first- or second-line oxaliplatin-based therapy with treatment failure or intolerance\*; Note: \*Treatment failure or intolerance is defined …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.